Abstract: Polymeric micelle of the A 3 B-type lactosome comprising (poly(sarcosine)) 3 -b-poly(L-lactic acid) was labeled with 111 In. The 111 In-labeled A 3 B-type lactosome was administered to the model mice bearing meningeal dissemination and bone metastasis at mandible. With single-photon emission computed tomography (SPECT) imaging, the meningeal dissemination was identified successfully by 111 In-labeled A 3 B-type lactosome, which was superior to 201 TlCl in regard of the imaging contrast. The 111 In-labeled A 3 B-type lactosome was also potential in imaging selectively of bone metastasis at mandible, whilst a nonspecific imaging of the whole bone was obtained by the SPECT imaging using 99m Tc-HMDP. The polymeric micelle of the A 3 B-type lactosome was therefore found to be effective as a vehicle of 111 In to be targeted to meningeal dissemination and bone metastasis.
Introduction
Meningeal metastasis, which develops in approximately 5-10% of cancer patients, is a fatal complication of lung cancer, breast cancer, and melanoma [1] . Melanoma of the skin, for example, will amount to 87,000 of the estimated new cancer cases in the United States, 2017 [2] , and 15% of the patients with melanoma suffer from central nervous system (CNS) metastasis with a dismal prognosis [3, 4] . Craniospinal Gd-MRI represents the gold standard for a neuroimaging diagnosis of leptomeningeal metastases, because fluid-attenuated inversion recovery or T2-weighted imaging is not so potential [5] . Single-photon emission computed tomography (SPECT) using thallous (Tl + ) ion is another diagnostic method for CNS metastasis, because tumor cells uptake Tl + ion, which has a similar size to K + , through the Na + -K + ATPase [6] . These diagnostic methods, however, cannot directly associate with therapeutic treatment of meningeal metastasis for which there is currently no cure. On the other hand, the concept of theranostics [7, 8] , in which a vehicle, such as antibody and nanoparticles, employed for delivery of diagnostic and therapeutic agents to the target sites, has been drawing much attention. One typical example is Zevalin ® , which uses a monoclonal antibody, Ibritumomab, as a delivery vehicle to non-Hodgkin lymphoma cells. 111 In-labeled Ibritumomab clarifies in vivo disposition of this antibody, which determines the dose of 90 Y-labled Ibritumomab for therapy [9] .
Nanoparticles are another candidate for cancer medicine as a vehicle, which is based on the inherent property of nanoparticles to accumulate in solid tumors in accordance with the enhanced Nanomaterials 2018, 8, 79 2 of 9 permeability and retention (EPR) effect [10] . There are, however, two major concerns on nanoparticles for theranostics: one is the low delivery efficiencies to tumor sites [11] and the other is the accelerated blood clearance (ABC) phenomenon, in which nanoparticles can become immunogenic after frequent doses [12, 13] , and efforts for nanoparticles to escape from the ABC phenomenon have been paid. The ABC phenomenon was observed with cynomolgus monkeys and minipigs especially at a low dosage [14, 15] . It is therefore considered that the ABC phenomenon would be observed in humans as well. Our group has reported that polymeric micelle of A 3 B-type lactosome composed of (poly(sarcosine) 3 )-b-poly(L-lactic acid) could overcome these problems owing to its small diameter of less than 30 nm and a high surface density of hydrophilic chains [16] [17] [18] [19] [20] . A 3 B-type lactosome is therefore examined here on the delivery ability to meningeal dissemination. A mouse model of melanoma metastases in brain was constructed by intra-cardiac injection of B16F10 cells resulting in exclusive ventricular and leptomeningeal spread [21, 22] . With this model, bone metastasis was also observed. A 3 B-type lactosome was prepared with mixing DOTA-poly(D-lactic acid) (DOTA-PDLA, DOTA is one of the commonly used chelator for a number of isotopes, including 111 In, 177 Lu, 86/90 Y, 225 Ac, and 44/47 Sc [23] ) to be labeled with 111 In. SPECT imaging of B16F10 meningeal dissemination by 111 In-labled A 3 B-type lactosome was compared with that by 201 TlCl. The ability of bone metastasis imaging by A 3 B-type lactosome was also evaluated and compared with SPECT imaging by 99m Tc-HMDP.
Results

Preparation of 111 In-Lactosome
111 In-lactosome was prepared by mixing with lyophilized DOTA-lactosome and 111 InCl 3 at 90 • C for five minutes, and was purified by PD-10 column chromatography ( Figure 1 ). With this column, free Indium ions were strongly bound to the resin to leave In-chelated lactosome alone in the eluent. The resulting yield of 111 In-lactosome was 79.6%. Nanoparticles are another candidate for cancer medicine as a vehicle, which is based on the inherent property of nanoparticles to accumulate in solid tumors in accordance with the enhanced permeability and retention (EPR) effect [10] . There are, however, two major concerns on nanoparticles for theranostics: one is the low delivery efficiencies to tumor sites [11] and the other is the accelerated blood clearance (ABC) phenomenon, in which nanoparticles can become immunogenic after frequent doses [12, 13] , and efforts for nanoparticles to escape from the ABC phenomenon have been paid. The ABC phenomenon was observed with cynomolgus monkeys and minipigs especially at a low dosage [14, 15] . It is therefore considered that the ABC phenomenon would be observed in humans as well. Our group has reported that polymeric micelle of A3B-type lactosome composed of (poly(sarcosine)3)-b-poly(L-lactic acid) could overcome these problems owing to its small diameter of less than 30 nm and a high surface density of hydrophilic chains [16] [17] [18] [19] [20] . A3B-type lactosome is therefore examined here on the delivery ability to meningeal dissemination. A mouse model of melanoma metastases in brain was constructed by intra-cardiac injection of B16F10 cells resulting in exclusive ventricular and leptomeningeal spread [21, 22] . With this model, bone metastasis was also observed. A3B-type lactosome was prepared with mixing DOTA-poly(D-lactic acid) (DOTA-PDLA, DOTA is one of the commonly used chelator for a number of isotopes, including 111 In, 177 Lu, 86/90 Y, 225 Ac, and 44/47 Sc [23] ) to be labeled with 111 In. SPECT imaging of B16F10 meningeal dissemination by 111 In-labled A3B-type lactosome was compared with that by 201 TlCl. The ability of bone metastasis imaging by A3B-type lactosome was also evaluated and compared with SPECT imaging by 99m Tc-HMDP.
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Melanoma Brain Metastases
B16F10-luc2 cells (1 × 10 5 in 0.1 mL of PBS) were injected from the left cardiac ventricle of fiveweek-old mice. Melanoma cells were migrated around the jaw and the knee joint at 11 days after implantation ( Figure 2A ). Brain metastases were confirmed by measuring of luminescence from 
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Comparison of 111 In-Lactosome and 201 TlCl for SPECT/CT Imaging
Since the SPECT imaging makes it possible to collect simultaneously the data of multiple radiation sources owing to measuring the different energy radiation with choosing proper filters, different radiation species can be compared regarding their imaging abilities using an identical mouse. Comparison of 111 In-lactosome and 201 TlCl for SPECT/CT imaging of the brain metastases were carried out using an identical mouse. No specific accumulation of radioactivity was observed in the brain for control mice having no injection of B16F10 cells ( Figure 3A) . On the contrary, both of 
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In Vivo Disposition in Brain
Radioactivities of 111 In-lactosome and 201 TlCl of the brains were measured by gamma counter using isolated brain to eliminate effects from bone metastases and muscle around the brain. Metastases to the facial bone were also generated upon intracardiac injection of B16F10-luc2 cells. 111 In-lactosome clearly imaged the metastasis at mandible as well (Figure 3 ). In the case of 201 TlCl, however, accumulation of radioactivity in the muscle around the neck was also observed, which makes it difficult to recognize the bone metastasis at mandible by Tl ion ( Figure 3A) . 99m Tc-HMDP accumulated a broad range of bones in head and neck ( Figure 3B ), and has difficulty in selective imaging of bone metastasis.
Radioactivities of 111 In-lactosome and 201 TlCl of the brains were measured by gamma counter using isolated brain to eliminate effects from bone metastases and muscle around the brain. Accumulation of radioactivities of 111 In-lactosome and 201 TlCl in brains of control mice were 0.311 ± 0.035 %ID/g and 0.354 ± 0.040 %ID/g, respectively. In contrast, accumulation of radioactivities of 111 In-lactosome and 201 TlCl in the brain metastases were 0.641 ± 0.126 %ID/g and 0.514 ± 0.086 %ID/g, respectively (Figure 4 ). 
Discussion
Brain metastases in the leptomeningeal and cerebral ventricle were observed when the B16F10 melanoma cells were injected in the left cardiac ventricle [22] . It was known that 111 In-lactosome accumulated in solid tumors by the EPR effect [24] . SPECT/CT images of brain metastases mice showed that 111 In-lactosome accumulated in the metastases of the leptomeningeal and cerebral ventricle. However, in the mechanism for the selective accumulation of 111 In-lactosome in the brain metastases, it is unclear whether 111 In-lactosome could accumulate in the brain metastases through the spinal fluid.
SPECT imaging using 201 TlCl has an intrinsic limitation because of its background uptake by muscle [25] . 99m Tc-HMDP also failed to accumulate in brain metastases. On the contrary, 111 Inlactosome accumulated selectively in both brain and bone metastases. In comparison with 201 TlCl, 111 In-lactosome accumulation in the healthy brain was extremely lowered. Assuming that the accumulation in the healthy brain was not affected by implantation of B16F10 cells, accumulation gains of 111 In-lactosome and 201 TlCl in the brain metastases compared with the healthy brain were estimated by the accumulation difference between them, and found to increase by 0.33%ID/g and 0.16%ID/g, respectively (Figure 4) . Since the accumulation amount of 111 In-lactosome in the brain metastases was doubled in comparison with that of 201 TlCl, the imaging ability of 111 In-lactosome is accordingly superior to 201 TlCl. 
SPECT imaging using 201 TlCl has an intrinsic limitation because of its background uptake by muscle [25] . 99m Tc-HMDP also failed to accumulate in brain metastases. On the contrary, 111 In-lactosome accumulated selectively in both brain and bone metastases. In-lactosome is composed of an A 3 B-type amphiphilic polydepsipeptide (A and B represent hydrophilic and hydrophobic blocks, respectively) of ((sarcosine) 42 ) 3 -b-(L-lactic acid) 30 . The molecular design of the A 3 B-type amphiphilic polydepsipeptide is explained as follows. The A 3 B-type amphiphilic polydepsipeptide generated polymeric micelles of the A 3 B-type lactosome with a high surface density of the hydrophilic poly(sarcosine) chains resulting in escape from recognition by immune system [19] . That is, the A 3 B-type lactosome shows unchanged in vivo dispositions upon frequent doses, whilst the AB-type lactosome with a low surface density failed and the accelerated blood clearance was observed at second dose [18] . The evasion ability of the A 3 B-type lactosome from the immune system was studied with varying the hydrophilic poly(sarcosine) chain length, and the optimum chain length was found to exist between 30 to 50 mer [26] . The chain length of the hydrophobic block of poly(L-lactic acid) was also chosen to be 30 mer because the chain length allows to take a helical conformation leading to a good molecular association between the hydrophobic blocks [27] . All the points of these molecular designs place an emphasis on raising the evade ability of the nanoparticle from the immune system, and they also lead to effective accumulations in solid tumors. Recently, we are observing the delivery pathway of the A 3 B-type amphiphilic polydepsipeptide to lymph node in healthy mice. The pathway to meningeal dissemination therefore may be via spinal fluid which is now under investigation.
Taken together, 111 In-lactosome has a high potential for selective imaging of brain and bone metastases, and therefore is applicable as a diagnostic agent. Further, 111 In-lactosome distributes to every site of meningeal dissemination. With replacement of 111 In with 90 Y, the obtainable 90 Y carrying lactosome will be applicable for therapeutic agent for meningeal dissemination, for which there is currently no cure. For this objective, the accumulation of 90 Y carrying lactosome in bone marrow should be low, which is now under investigation.
Materials and Methods
Polymer Synthesis
DOTA-PDLA (PDLA represents poly(D-lactic acid); number-average molecular weight (M n which was estimated by NMR) = 2.2 × 10 3 (30 mer) was synthesized by condensation of NH 2 -PDLA and tri-tert-butyl 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate as described previously [24] . Tri-tert-butyl groups were deprotected with trifluoroacetic acid. The A 3 B-type amphiphilic block polydepsipeptide of (poly(sarcosine)) 3 -block-poly(L-lactic acid) (P(Sar 42 )) 3 -PLLA 30 ; M n values of poly(sarcosine) and poly(L-lactic acid) blocks were 3.0 × 10 3 (42 mer) and 2.2 × 10 3 (30 mer), respectively) was similarly synthesized as described previously [26, 28] .
Animal and Cell Line
Mouse melanoma cell line (B16F10-luc2) was purchased from Caliper Life Sciences (Hopkinton, MA, USA). B16F10-luc2 cells were cultured in DMEM medium supplemented with 10% FBS, 1% GlutaMAX™ (Invitrogen, Carlsbad, CA, USA), 2.5 µg/mL Plasmocin™ Prophylactic (Nacalai Tesque, Kyoto, Japan), 100 U/mL penicillin, and 100 µg/mL streptomycin. Cells were incubated in a 5% CO 2 -humidified incubator at 37 • C. Pathogen-free male athymic BALB/c nude mice were purchased from the Japan SLC (Shizuoka, Japan). The brain metastasis model was established by injecting tumor cells (1 × 10 5 in 0.1 mL of PBS) into the left cardiac ventricle of 5-week-old mice anesthetized by intraperitoneal injection of pentobarbital sodium. All the animal experiments were approved by the Animal Research Committee of Kyoto University.
Preparation of 111 In-Lactosome
Four milligrams of (P(Sar 42 )) 3 -PLLA 30 and 2 mol% of DOTA-PDLA were dissolved in 2 mL of chloroform. After the polymers were completely dissolved, distill chloroform off under reduced pressure using a rotary evaporator (RE300, Yamato Scientific, Tokyo, Japan). Then 2 mL ultra-pure water was added into the dried polymer film. The self-assembled polymer micelles were obtained by sonication of polymer solution for 2 min at 85 • C. The self-assembled polymeric micelle composed of (P(Sar 42 )) 3 -PLLA 30 and DOTA-PDLA (DOTA-lactosome) was lyophilized and stored until use. 0.1 M sodium acetate was added into 111 InCl 3 solution (Nihon Medi-Physics, Tokyo, Japan) to adjust pH at 4.7 before labeling of 111 In to DOTA. 111 In labeled DOTA-PDLA containing A 3 B-type lactosome ( 111 In-lactosome) was prepared by mixing 1 mg of lyophilized DOTA-lactosome and 0.7 mL of 111 InCl 3 solution at pH 4.7 and heated at 90 • C for 5 min. 111 In-lactosome was purified by PD-10 column chromatography (GE Helthcare, Little Chalfont, UK) using saline to remove 111 In ions that did not incorporate in DOTA (Figure 1) . 111 In-lactosome was concentrated by centrifugal concentrator (Amicon Ultra 50 kDa, Merck Millipore, Burlington, MA, USA) if necessary. Characterizations of the polymeric micelles were reported before [19, 26, 28] , and they were as follows: hydrodynamic diameter by DLS: ca. 25 nm, critical association concentration: ca. 8 × 10 −7 M.
Imaging of Melanoma Metastasis
The B16F10 implanted mice were used for single-photon emission computed tomography/computed tomography (SPECT/CT) imaging at 13 days after cell injection. Luminescence images of whole body of mouse and isolated brain were obtained with mice at 11 days and 14 days after intracardiac cell injection, respectively. The SPECT/CT images for isolated brains were taken at 24 h after intravenous injection of 111 In-lactosome (12.8-13.7 MBq/body). An iodinated contrast agent (Iomeron350, Eisai, Tokyo, Japan) for CT was also used 437. 
In Vivo Disposition in Brain
The B16F10 implanted mice were used for in vivo disposition in brain at 13 days after cell injection. The in vivo dispositions of 111 In-lactosome and 201 TlCl were determined in metastatic melanoma bearing and intact mice (n = 10). 111 In-lactosome and 201 TlCl of more than 0.5 MBq was injected into the identical mouse via tail vein. 111 In-lactosome and 201 TlCl were injected at 24 h and 20 min before the resection of brain, respectively. Radioactivities of 111 In and 201 Tl were detected in a gamma counter (COBRA II, Packard Instrument, Meriden, CT, USA) with energy window of 220-270 keV and 63-77 keV, respectively. The distribution of radioactivity measured and calculated for the percentage of injected dose of radioactivity per gram of tissue (%ID/g). Differences were considered statistically significant when p values were less than 0.05.
Statistical Analysis
All results are expressed as mean ± SD. Differences between groups were assessed by the t test for independent samples. p values < 0.05 were considered statistically significant.
Ethics
All of our in vivo animal experiments were approved by the Animal Research Committee of Kyoto University. Animals were treated humanely.
Conclusions
111 In-labeled A 3 B-type lactosome accumulated selectively in the brain metastases of the leptomeningeal and the cerebral ventricle and in bone metastasis. Since 111 In-labeled A 3 B-type lactosome distributed negligibly into healthy brain, bone and muscle, the SPECT imaging contrast for metastasis in the head and neck was highly potential by 111 In-labeled A 3 B-type lactosome compared with 201 TlCl and 99m Tc-HMDP SPECT imaging.
